Premiere Date: December 20, 2015
Expiration Date: June 20, 2017
This activity offers CE credits for:
1. Physicians (CME)
This article reviews DSM-5 changes to symptom criteria for bipolar disorder. The primary focus is on treatment of bipolar depression and cyclothymic disorder.
At the end of this CE activity, participants should be able to:
• Identify the 4 FDA-approved medications for bipolar depression
• Identify FDA-approved medication for maintenance therapy of depression in bipolar disorder
• Distinguish which antidepressants to avoid to minimize the risk of mood destabilization
This continuing medical education activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with mental health disorders.
CME Credit (Physicians): This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters, LLC, and Psychiatric Times. CME Outfitters, LLC, is accredited by the ACCME to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners and Physician Assistants: AANPCP and AAPA accept certificates of participation for educational activities certified for 1.5 AMA PRA Category 1 Credit™.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer-review process.
The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Philip G. Janicak, MD, reports that he has received grant support from, and is on the speakers bureau for, Neuronetics Inc, Sunovion, and Ortho-McNeil/Janssen; he is also a consultant for Neuronetics Inc.
Joseph Esposito, MS, MD, has no disclosures to report.
Michael Gilin, MD, (peer/content reviewer) reports that he is on the speakers bureau for Otsuka.
Applicable Psychiatric Times staff and CME Outfitters staff have no disclosures to report.
UNLABELED USE DISCLOSURE
Faculty of this CME/CE activity may include discussion of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA-labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity?
Call us at 877.CME.PROS (877.263.7767)
Dr Janicak is Director of the Transcranial Magnetic Stimulation Center at Edward/Elmhurst Healthcare and is on the faculty of the department of psychiatry and behavioral sciences at Northwestern University Feinberg School of Medicine in Chicago; Dr Esposito is a first-year resident at the Delaware Psychiatric Center in New Castle, Del.
1. Janicak JG, Esposito J. An update on the diagnosis and treatment of bipolar disorder, part 1: mania. Psychiatric Times. November 2015;32:29-35.
2. Frankland A, Cerrillo E, Hadzi-Pavlovic D, et al. Comparing the phenomenology of depressive episodes in bipolar I and II disorder and major depressive disorder within bipolar disorder pedigrees. J Clin Psychiatry. 2015;76:32-39.
3. Citrome L. Treatment of bipolar depression: making sensible decisions. CNS Spectr. 2014;19(suppl 1):4-11.
4. Silva MT, Zimmermann IR, Galvao TF, Pereira MG. Olanzapine plus fluoxetine for bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2013;146:310-318.
5. Detke HC, DelBello MP, Landry J, Usher RW. Olanzapine/fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. J Am Acad Child Adol Psychiatry. 2015;54:217-224.
6. Tohen M, Kanba S, McIntyre RS, et al. Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features. J Affect Disord. 2014;164:57-62.
7. Tohen M, Katagiri H, Fujikoshi S, Kanba S. Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies. J Affect Disord. 2013;149:196-201.
8. Wang M, Tong JH, Huang DS, et al. Efficacy of olanzapine monotherapy for treatment of bipolar I depression: a randomized, double-blind, placebo controlled study. Psychopharmacol. 2014;231:2811-2818.
9. Pan PY, Lee MS, Lo MC, et al. Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study. BMC Psychiatry. 2014;14:145.
10. Suttajit S, Srisurapanont M, Maneeton N, Maneeton B. Quetiapine for acute bipolar depression: a systematic review and meta-analysis. Drug Des Develop Ther. 2014;8:827-838.
11. Suppes T, Vieta E, Gustafsson U, Ekholm B. Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials. Depress Anxiety. 2013;30:1089-1098.
12. Young AH, McElroy SL, Olausson B, et al. A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World J Biol Psychiatry. 2014;15:96-112.
13. Findlay LJ, El-Mallakh P, El-Mallakh RS. Management of bipolar I depression: clinical utility of lurasidone. Therapeut Clin Risk Manage. 2015;11:75-81.
14. Fountoulakis KN, Gazouli M, Kelsoe J, Akiskal H. The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder. Eur Neuropsychopharmacol. 2014; [Epub ahead of print].
15. McIntyre RS, Cucchiaro J, Pikalov AA, et al. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry. 2015;76:398-405.
16. Smith LA, Cornelius VR, Azorin JM, et al. Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord. 2010;122:1-9.
17. Mockenhaupt M, Messenheimer J, Tennis P, et al. Risk of SJS and TEN in new users of antiepileptics. Neurology. 2005;64:1134-1138.
18. Vieta E, Valenti M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs. 2013;27:515-529.
19. Bowden CL, Singh V. Lamotrigine (Lamictal IR) for the treatment of bipolar disorder. Exp Opin Pharmacother. 2012;13:2565-2571.
20. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64:1013-1024.
21. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60:392-400.
22. Machado-Vieira R, Zanetti MV, DeSousa RT, et al. Lithium efficacy in bipolar depression with flexible dosing: a six-week, open-label, proof-of-concept study. Exp Ther Med. 2014;8:1205-1208.
23. Nolen WA. More robust evidence for the efficacy of lithium in the long-term treatment of bipolar disorder: should lithium (again) be recommended as the single preferred first-line treatment? In J Bipolar Disord. 2015;3:1.
24. Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry. 2011;72:156-167.
25. Garrett AS, Miklowitz DJ, Howe ME, et al. Changes in brain activation following psychotherapy for youth with mood dysregulation at familial risk for bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2015;56:215-220.
26. Bauer MS, McBride L, Williford WO, et al. Collaborative care for bipolar disorder: part I. Intervention and implementation in a randomized effectiveness trial. Psychiat Serv. 2006;57:927-936.
27. Bauer MS, McBride L, Williford WO, et al. Collaborative care for bipolar disorder, part II. Impact on clinical outcome, function, and costs. Psychiat Serv. 2006;57:937-945.
28. Parikh SV, Hawke LD, Velyvis V, et al. Combined treatment: impact of optimal psychotherapy and medication in bipolar disorder. Bipolar Disord. 2015;17:86-96.
29. Miklowitz DJ, Otto MW, Wisniewski SR, et al. Psychotherapy, symptom outcomes, and role functioning over one year among patients with bipolar disorder. Psychiat Serv. 2006;57:959-965.
30. Brown NC, Andreazza AC, Young LT. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res. 2014;218:61-68.
31. Harvey AG, Kaplan KA, Soehner A. Interventions for sleep disturbance in bipolar disorder. Sleep Med Clin. 2015;10:101-105.
32. Harvey AG, Soehner AM, Kaplan KA, et al. Treating insomnia improves mood state, sleep, and functioning in bipolar disorder: a pilot randomized controlled trial. J Consult Clin Psychol. 2015;83:564-577.
33. Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015;17:63-75.
34. Veselinovic T, Paulzen M, Grunder G. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Exp Rev Neurotherapeut. 2013;13:1141-1159.
35. Gigante AD, Bond DJ, Lafer B, et al. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord. 2012;14:478-487.
36. Serra G, Koukopoulos A, De Chiara L, et al. Three-year, naturalistic, mirror-image assessment of adding memantine to the treatment of 30 treatment-resistant patients with bipolar disorder. J Clin Psychiatry. 2015;76:e91-e97.
37. Ionescu DF, Luckenbaugh DA, Niciu MJ, et al. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disord. 2014: [Epub ahead of print].
38. Zarate CA, Jr, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71:939-946.
39. Rapinesi C, Bersani FS, Kotzalidis GD, et al. Maintenance deep transcranial magnetic stimulation sessions are associated with reduced depressive relapses in patients with unipolar or bipolar depression. Front Neurol. 2015;6:16.
40. Pallanti S, Grassi G, Antonini S, et al. rTMS in resistant mixed states: an exploratory study. J Affect Disord. 2014;157:66-71.
41. Agarkar S, Mahgoub N, Young RC. Use of transcranial magnetic stimulation in bipolar disorder. J Neuropsychiatry Clin Neurosci. 2011;23:E12-E13.
42. Loo C, Greenberg B, Mitchell P. Nonpharmacotherapeutic somatic treatments for bipolar disorder (ECT, DBS, rTMS). Curr Topics Behav Neurosci. 2011;5:285-302.
43. Holtzheimer PE, Kelley ME, Gross RE, et al. Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch Gen Psychiatry. 2012;69:150-158.
44. Janicak PG, Marder SR, Pavuluri MN. Principles and Practice of Psychopharmacotherapy. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011.